Terns Pharmaceuticals (TERN) News Today $6.17 -0.38 (-5.80%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Research Analysts Set Expectations for TERN FY2024 EarningsNovember 17 at 1:13 AM | americanbankingnews.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 8.7% - Should You Sell?Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 8.7% - Should You Sell?November 15 at 4:14 PM | marketbeat.comWe Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business GrowthNovember 15 at 6:15 AM | finance.yahoo.comWhat is HC Wainwright's Forecast for TERN FY2024 Earnings?Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Terns Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per shaNovember 15 at 6:04 AM | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Given New $7.50 Price Target at HC WainwrightNovember 15 at 1:52 AM | americanbankingnews.comBrokers Issue Forecasts for TERN Q1 EarningsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Terns Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst E. Arce anticipates that the company will earn ($November 14 at 9:14 AM | marketbeat.comTerns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy RatingNovember 14 at 12:45 AM | markets.businessinsider.comPromising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns PharmaceuticalsNovember 14 at 12:45 AM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Revolution Medicines (RVMD)November 8, 2024 | markets.businessinsider.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issuedOctober 31, 2024 | marketbeat.comOppenheimer Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)Oppenheimer started coverage on shares of Terns Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $82.00 target price on the stock.October 31, 2024 | marketbeat.comTerns Pharmaceuticals: Another Potential GLP-1 EntrantOctober 21, 2024 | seekingalpha.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Short Interest UpdateTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,910,000 shares, an increase of 30.6% from the September 15th total of 3,760,000 shares. Approximately 8.3% of the shares of the company are sold short. Based on an average trading volume of 1,930,000 shares, the days-to-cover ratio is presently 2.5 days.October 14, 2024 | marketbeat.comMarshall Wace LLP Decreases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Marshall Wace LLP cut its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 86.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,985 shares of the company's stock after sellinOctober 13, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 6.2% - Should You Sell?Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 6.2% - What's Next?October 10, 2024 | marketbeat.comRenaissance Technologies LLC Takes Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Renaissance Technologies LLC bought a new position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 87,500 shares of the company's stoOctober 10, 2024 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)October 7, 2024 | globenewswire.comTerns Pharma (NASDAQ:TERN) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 21.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,690,376 shares of the company's stock after puSeptember 30, 2024 | marketbeat.comShort Interest in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Increases By 41.4%Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 3,760,000 shares, an increase of 41.4% from the August 31st total of 2,660,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 1.9 days. Currently, 6.4% of the shares of the company are sold short.September 27, 2024 | marketbeat.comGreat Point Partners LLC Sells 160,569 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Great Point Partners LLC lessened its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 12.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,149,406 shares of the company's stock aftSeptember 24, 2024 | marketbeat.comTerns Pharmaceuticals Inc (430.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp increased its holdings in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 56.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 176,673 shares of the companSeptember 21, 2024 | marketbeat.comThis Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss TreatmentsSeptember 18, 2024 | fool.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Buys $4,999,995.00 in StockSeptember 18, 2024 | insidertrades.comTerns Pharmaceuticals (NASDAQ:TERN) Trading Up 6.1%Terns Pharmaceuticals (NASDAQ:TERN) Trading 6.1% HigherSeptember 17, 2024 | marketbeat.comOrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals IncSeptember 17, 2024 | finance.yahoo.comWith 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backingSeptember 17, 2024 | finance.yahoo.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up to $8.95Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up to $8.95September 16, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Earns "Outperform" Rating from BMO Capital MarketsBMO Capital Markets reaffirmed an "outperform" rating and set a $26.00 price objective (up from $19.00) on shares of Terns Pharmaceuticals in a research note on Monday.September 16, 2024 | marketbeat.comMissed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.September 15, 2024 | fool.comShould You Invest in This Under-the-Radar Weight Loss Stock?September 15, 2024 | fool.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Short Interest Up 47.8% in AugustTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totalling 2,660,000 shares, an increase of 47.8% from the August 15th total of 1,800,000 shares. Approximately 5.6% of the company's stock are short sold. Based on an average trading volume of 1,780,000 shares, the days-to-cover ratio is currently 1.5 days.September 14, 2024 | marketbeat.com1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or MoreSeptember 14, 2024 | fool.comTerns Pharmaceuticals (NASDAQ:TERN) Sees Unusually-High Trading VolumeTerns Pharmaceuticals (NASDAQ:TERN) Sees Strong Trading VolumeSeptember 13, 2024 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Sells $110,000.00 in StockSeptember 13, 2024 | insidertrades.comTerns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 12, 2024 | globenewswire.comMark J. Vignola Sells 10,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 10,000 shares of the firm's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $11.00, for a total value of $110,000.00. Following the sale, the chief financial officer now directly owns 91,940 shares of the company's stock, valued at $1,011,340. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.September 12, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)September 12, 2024 | markets.businessinsider.comBiotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & MoreSeptember 12, 2024 | msn.comTerns Pharmaceuticals (NASDAQ:TERN) Trading Down 4% Following Insider SellingTerns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 4% After Insider SellingSeptember 12, 2024 | marketbeat.comInsider Selling: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Sells 17,235 Shares of StockSeptember 12, 2024 | insidertrades.comWeight-loss drug boom sparks battle over pharmacy copycatsSeptember 11, 2024 | msn.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley Sells 17,235 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 17,235 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $10.00, for a total transaction of $172,350.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at approximately $150,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.September 11, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Down to $11.23Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Down to $11.23September 11, 2024 | marketbeat.comTerns Pharmaceuticals Shares Fall After Pricing of Public OfferingSeptember 11, 2024 | marketwatch.comTerns Announces Pricing of Upsized $150.15 Million Public OfferingSeptember 10, 2024 | globenewswire.comTerns Pharmaceuticals: Weight Loss Drug TERN-601 Is CompetitiveSeptember 10, 2024 | seekingalpha.comTerns Pharmaceuticals (NASDAQ:TERN) Sets New 1-Year High Following Analyst UpgradeTerns Pharmaceuticals (NASDAQ:TERN) Reaches New 52-Week High After Analyst UpgradeSeptember 10, 2024 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Price Target Raised to $20.00 at JMP SecuritiesJMP Securities raised their target price on Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a "market outperform" rating in a report on Tuesday.September 10, 2024 | marketbeat.com Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… TERN Media Mentions By Week TERN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼1.150.56▲Average Medical News Sentiment TERN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼173▲TERN Articles Average Week Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aquestive Therapeutics News Today Inozyme Pharma News Today Enanta Pharmaceuticals News Today Enzo Biochem News Today LAVA Therapeutics News Today NextCure News Today Bolt Biotherapeutics News Today Mirum Pharmaceuticals News Today Harmony Biosciences News Today Wave Life Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TERN Stock Alerts